{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Lung+Neuroendocrine+Neoplasm", "query": { "condition": "Recurrent Lung Neuroendocrine Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 89, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Lung+Neuroendocrine+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T21:27:17.674Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Adenocarcinoma", "Human Papillomavirus-Related Anal Squamous Cell Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Merkel Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Stage III Merkel Cell Carcinoma AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Pleural Malignant Mesothelioma AJCC v7", "Stage IV Merkel Cell Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IV Pleural Malignant Mesothelioma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-03-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074513" }, { "nct_id": "NCT01386580", "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Metastases", "Lung Cancer", "Breast Cancer", "Melanoma", "Malignant Glioma" ], "interventions": [ { "name": "2B3-101", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "2B3-101 60 mg/m2 every 4 weeks", "type": "DRUG" }, { "name": "2B3-101 50 mg/m2 every 3 weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BBB-Therapeutics B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2011-07", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01386580" }, { "nct_id": "NCT00049296", "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-07", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049296" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT00004065", "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004065" }, { "nct_id": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "tipifarnib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 2, "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005842" }, { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT05573035", "title": "A Study to Investigate LYL845 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LYL845", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2022-12-19", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 18, "location_summary": "Sacramento, California • Santa Monica, California • Stanford, California + 14 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573035" }, { "nct_id": "NCT03154190", "title": "Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Brain Glioblastoma", "Estrogen Receptor Negative", "Extensive Stage Small Cell Lung Carcinoma", "Head and Neck Carcinoma", "HER2/Neu Negative", "Hormone-Resistant Prostate Cancer", "Limited Stage Small Cell Lung Carcinoma", "Myelodysplastic Syndrome", "Progesterone Receptor Negative", "Progressive Disease", "Recurrent Carcinoma", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage III Colon Cancer", "Stage III Esophageal Cancer", "Stage III Gastric Cancer", "Stage III Non-Small Cell Lung Cancer", "Stage III Ovarian Cancer", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Skin Melanoma", "Stage IIIA Colon Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Rectal Cancer", "Stage IIIA Skin Melanoma", "Stage IIIB Colon Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Rectal Cancer", "Stage IIIB Skin Melanoma", "Stage IIIC Colon Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Rectal Cancer", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Bone Sarcoma", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Ovarian Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IV Soft Tissue Sarcoma", "Stage IVA Bone Sarcoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Bone Sarcoma", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Supportive Care", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2017-08-08", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-06-25T21:27:17.674Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154190" } ] }